Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 21

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 21
---
Collaborations and licenses$280 $767 $11,809 $2,861 Non-cash royalty revenue249 572 1,223 1,736 Total Revenue529 1,339 13,032 4,597 Operating expenses Research and development5,778 14,273 20,235 45,227 General and administrative3,044 4,537 12,204 17,396 Change in fair value of contingent consideration268 344 827 735 Restructuring costs98 3,625 12,636 3,625 Total operating expenses9,188 22,779 45,902 66,983 Loss from operations(8,659)(21,440)(32,870)(62,386)Other incomeInterest income952 1,747 3,191 5,121 Interest expense(23)(29)(79)(107)Foreign exchange (loss) gain(12)5 13 (16)Total other income917 1,723 3,125 4,998 Net loss$(7,742)$(19,717)$(29,745)$(57,388)Net loss per common share  Basic and diluted$(0.04)$(0.10)$(0.16)$(0.31)Weighted average number of common shares  Basic and diluted191,778,950 188,997,194 191,347,969 184,244,819 Comprehensive lossUnrealized gain on available-for-sale securities$58 $218 $6 $331 Comprehensive loss$(7,684)$(19,499)$(29,739)$(57,057)

See accompanying notes to the condensed consolidated financial statements.

2

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

Common Shares Number of SharesShare CapitalAdditional Paid-In CapitalDeficitAccumulated Other Comprehensive LossTotal Stockholders' EquityBalance December 31, 2024189,963,492 $1,410,025 $82,048 $(1,346,572)$(48,135)$97,366 Stock-based compensation expense— — 3,564 — — 3,564 Issuance of common shares pursuant to exercise of options892